- Case Report
- Open Access
Chronic tophaceous gout presenting as acute arthritis during an acute illness: a case report
© Dhoble et al; licensee BioMed Central Ltd. 2008
- Received: 09 October 2008
- Accepted: 15 October 2008
- Published: 15 October 2008
Gout is a metabolic disease that can manifest as acute or chronic arthritis, and deposition of urate crystals in connective tissue and kidneys. It can either manifest as acute arthritis or chronic tophaceous gout.
We present a 39-year-old male patient who developed acute arthritis during his hospital course. Later on, after a careful physical examination, patient was found to have chronic tophaceous gout. The acute episode was successfully treated with colchicines and indomethacin.
Gout usually flares up during an acute illness, and should be considered while evaluating acute mono articular arthritis. Rarely, it can also present with tophi as an initial manifestation.
- Uric Acid
- Serum Uric Acid
- Uric Acid Level
Gout is a metabolic disease, which is characterized by acute or chronic arthritis, and deposition of monosodium urate crystals in joint, bones, soft tissues, and kidneys [1–4]. In 18th century, Garrod proposed a causative relationship between elevated uric acid and urate crystal formation, which is underlying pathology for gout . Gout can either manifest as acute arthritis or chronic arthropathy, which is also called tophaceous gout [1, 2, 5].
A 39-year-old African American male patient was admitted with one-day history of acute left lower quadrant pain, and was diagnosed with acute uncomplicated diverticulitis, confirmed by computed tomography (CT) of the abdomen. His medical and surgical history was unremarkable, and he denied any medication use. He denied smoking or illicit drug use, but admitted occasional alcohol use on every other weekend. He did not follow any particular diet. He had an average built with BMI of 29.6. He was started on intravenous antibiotics and pain medication, which led to significant clinical improvement within two days.
Laboratory values at admission.
White blood count
Synovial fluid analysis.
WBC (per mm3)
Total protein (g/dL)
105 – 333
Monosodium urate crystals
The patient responded partially to colchicine, but later had great relief with indomethacin. Colchicine was used at the dose of 0.6 mg every two hourly. He received total of six doses, but it was stopped because he developed severe nausea and vomiting. He admitted that his pain was reduced to 4/10 in intensity from 9/10 before treatment, but swelling was persistent. We initiated indomethacin at 50 mg every eight hourly, and his pain and swelling was relieved to great extent in 48 hours.
Gout is a metabolic disease that can manifest as acute or chronic arthritis, and deposition of urate crystals in connective tissue and kidneys. All patients have hyperuricemia at some point of their disease. But, either normal or low serum uric acid levels can occur at the time of acute attack; and asymptomatic hyperuricemic individuals may never experience a clinical event resulting from urate crystal deposition [1–4]. Low to normal uric acid concentration can be due to excessive excretion of uric acid, crystal formation, or systemic inflammatory state [6, 7]; however, exact mechanism is still not completely understood. A diagnosis of gout is most accurate when supported by visualization of uric acid crystals in a sample of joint or bursal fluid, or demonstrated histologically in excised tissue. Synovial fluid analysis of our patient was consistent with inflammatory arthritis. Mild leucocytosis in this patient was due to systemic inflammatory response.
Visible or palpable tophi, as this patient exhibited, are usually noted only among those patients who are hyperuricemic and have had repeated attacks of acute gout, often over many years. However, presentation of tophaceous deposits in the absence of gouty arthritis is also reported [5, 8]. Pain and inflammation are manifested when uric acid crystals activate the humoral and cellular inflammatory processes .
During an acute illness, if systemic inflammatory state prevails, such as in an acute infection, cytokines and chemokines triggers inflammation and cause arthritis in the presence of urate crystals [10, 11]. Phagocytosis of these crystals by macrophages in the synovial lining cells precedes influx of neutrophils in the joint [9–11]. This process releases various mediators of inflammation locally [12, 13].
Hyperuricemia is often present in patients with tophaceous gout, and they can benefit from uric acid lowering therapy early during the course [14, 15]. In our patient, serum uric acid and 24-hour urine uric acid level was within normal limits when measured in the hospital before his discharge from the hospital. It was decided to follow him up in the clinic in two weeks, and measure these values again during 'interval gout' before deciding to start him on any particular medication to prevent further attacks of acute arthritis.
Our patient presented with tophi as an initial presentation of gout, which is very rare, but has been reported [5, 8]. Investigational studies due to acute elbow joint pain deciphered the underlying mystery of chronic swelling. Systemic inflammatory response secondary to diverticulitis exposed the joints to the effects of urate.
First-line treatments for an acute flare are either oral colchicine and/or non-steroidal anti-inflammatory agents. Systemic or intra-articular corticosteroids can also be used, and are equally effective, but with more side effects [16, 17]. Interleukin-1 inhibitors are still under investigation, and are not approved for an acute attack of gout .
Gout usually flares up during an acute illness, and should always be considered while evaluating acute mono articular arthritis in hospitalized patients. Gout can present with tophi as an initial manifestation of the disease process.
Written informed consent was obtained from the patient for publication of this case report and accompanying images in Journal of Medical Case Reports. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
We thank patient for giving us consent for the publication of the case report.
- Campion EW, Glynn RJ, DeLabry LO: Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med. 1987, 82: 421-10.1016/0002-9343(87)90441-4.View ArticlePubMedGoogle Scholar
- Hall AP, Barry PE, Dawber TR, McNamara PM: Epidemiology of gout and hyperuricemia: A long term population study. Am J Med. 1967, 42: 27-10.1016/0002-9343(67)90004-6.View ArticlePubMedGoogle Scholar
- Logan JA, Morrison E, McGill PE: Serum uric acid in acute gout. Ann Rheum Dis. 1997, 56: 696-7.PubMed CentralView ArticlePubMedGoogle Scholar
- Garrod AB: The Nature and Treatment of Gout and Rheumatic Gout. 1863, 2Google Scholar
- Wernick R, Winkler C, Campbell S: Tophi as the initial manifestation of gout. Report of six cases and review of literature. Arch intern med. 1992, 152: 873-10.1001/archinte.152.4.873.View ArticlePubMedGoogle Scholar
- Urano W, Yamanaka H, Tsutani H, Nakajima H, Matsuda Y, Taniguchi A, Hara M, Kamatani N: The inflammatory process in the mechanism of decreased serum uric acid concentrations during acute gouty arthritis. J Rheumatol. 2002, 29 (9): 1950-3.PubMedGoogle Scholar
- Simkin PA: The pathogenesis of podagra. Ann Intern Med. 1977, 86: 230.View ArticlePubMedGoogle Scholar
- Hollingworth P, Scott JT, Burry HC: Nonarticular gout: hyperuricemia and tophus formation without gouty arthritis. Arthritis Rheum. 1983, 26: 98-101. 10.1002/art.1780260117.View ArticlePubMedGoogle Scholar
- Beutler A, Schumacher HR: Gout and 'pseudogout': when are arthritic symptoms caused by crystal disposition?. Postgrad Med. 1994, 95: 103-6.PubMedGoogle Scholar
- Schumacher HR, Phelps P, Agudelo CA: Urate crystal induced inflammation in dog joints: sequence of synovial changes. J Rheumatol. 1974, 1: 102.PubMedGoogle Scholar
- Gordon TP, Kowanko IC, James M, Roberts-Thomson PJ: Monosodium urate crystal-induced prostaglandin synthesis in the rat subcutaneous air pouch. Clin Exp Rheumatol. 1985, 3: 291.PubMedGoogle Scholar
- Malawista SE, Duff GW, Atkins E, Cheung HS, McCarty DJ: Crystal-induced endogenous pyrogen production. A further look at gouty inflammation. Arthritis Rheum. 1985, 28: 1039-10.1002/art.1780280911.View ArticlePubMedGoogle Scholar
- Falasca GF, Ramachandrula A, Kelley KA, O'onnor CR, Reginato AJ: Superoxide anion production and phagocytosis of crystals by cultured endothelial cells. Arthritis Rheum. 1993, 36: 105-10.1002/art.1780360118.View ArticlePubMedGoogle Scholar
- Sutaria S, Katbamna R, Underwood M: Effectiveness of interventions for the treatment of acute and prevention of recurrent gout – a systematic review. Rheumatology (Oxford). 2006, 45: 1422-10.1093/rheumatology/kel071.View ArticleGoogle Scholar
- Wallace SL, Singer JZ: Therapy in gout. Rheum Dis Clin North Am. 1988, 14: 441.PubMedGoogle Scholar
- Janssens HJ, Janssen M, Lisdonk van de EH, van Riel PL, van Weel C: Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet. 371 (9627): 1854-60. 10.1016/S0140-6736(08)60799-0. 2008 May 31Google Scholar
- Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Lioté F, McCarthy G, Netter P, Nuki G, Perez-Ruiz F, Pignone A, Pimentão J, Punzi L, Roddy E, Uhlig T, Zimmermann-Gòrska I, EULAR Standing Committee for International Clinical Studies Including Therapeutics: EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006, 65 (10): 1312-24. 10.1136/ard.2006.055269.PubMed CentralView ArticlePubMedGoogle Scholar
- So A, De Smedt T, Revaz S, Tschopp J: A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther. 2007, 9: R28-10.1186/ar2143.PubMed CentralView ArticlePubMedGoogle Scholar